Nonlegal, judicial, and statutory courses of action are available to patient surrogates and physicians who cannot agree on withdrawal of life-sustaining treatment.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Physicians’ ethical obligations to disclose conflicts of interest to patients and to obtain their informed consent for treatment are particularly critical when proposed treatments are experimental.
Parents’ right to choose the culture of their children and a child’s right to an open future outweigh the right of the Deaf to perpetuate their culture by disallowing government funding of cochlear implant research to restore hearing.
Clinical case and commentary on how physicians should respond when confronted by medication requests from parents of children with mood and concentration disorders.
Anne-Marie Laberge, MD, MPH and Wylie Burke, MD, PhD
Two physicians examine the risks of testing minor children for late-onset genetic diseases when there is no current benefit and explain why several medical associations oppose the practice.
Physicians should fully understand the ethical principles and professional standards involved in making decisions for the treatment of impaired newborns.
Physicians should understand and be sensitive to all of the issues that affect patients when they prescribe the tertogenic medication isotretinoin for treatment of acne vulgaris.